OR WAIT null SECS
An independent report released by the European Medicines Agency highlighted a number of recommendations to aid the agency in its communication of the benefits and risks of medicines.
An independent report released by the European Medicines Agency on May 31, 2011, highlighted a number of recommendations to aid the agency in its communication of the benefits and risks of medicines. The report was the conclusion to a one-year project conducted by Frederic Bouder, PhD, at the behest of EMA, aiming to provide detailed, evidence-based input by analyzing the expectations and attitudes of the agency’s stakeholders toward communication on medicines.
Tackling a number of questions, including how current communication channels build or undermine trust, how the risk communication process could be improved and how that process could bridge the gap between opposite views and expectations, the research studied a population that included regulators, industry and third parties (e.g., patient and consumer organizations, scientific opinion leaders, and medical and nonmedical journalists and editors).
Bouder created three case studies around Viracept, Acomplia, and Gardasil, and also conducted a cross-case analysis. The report concluded with four main recommendations:
The agency has already started to implement some of the findings—evidence of its commitment to the five-year